Global segment ranking · Healthtech › Medtech
The world’s most valuable in-vitro diagnostics startups
Companies whose main business is testing samples of blood, urine, saliva or tissue: laboratory and point-of-care diagnostics, blood-based cancer detection, rapid infection and sepsis tests, at-home test kits and consumer blood testing. Ranked worldwide by AI-estimated valuation, with listed pure players shown in grey at their market value for reference. The market sets the value; AI models estimate it.
Key metrics for this segment: key milestone. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.
Not in this segment. Listed, so not ranked: Natera, Guardant Health, GRAIL and Freenome (shown in grey), and Molbio Diagnostics. Bought: Exact Sciences (Abbott), Sherlock Biosciences (OraSure), Lucira. Delisted or closed: Talis Biomedical, Cue Health. In other segments: Owkin under AI drug discovery, Mammoth Biosciences under Gene & cell therapies, body-scan clinics (Neko Health, Prenuvo) under Imaging & medical AI. A company appears in one segment only. Method
The segment at a glance
25companies ranked
2companies on the radar
13countries in the ranking
4listed benchmarks
Rankings by region
Filter the ranking and the Radar. Ranks stay worldwide. Regional pages: Asia · Europe · Latin America & Caribbean · Middle East & North Africa · North America · Sub-Saharan Africa.Global ranking · In-vitro diagnostics
Snapshot28 Oct 2026A snapshot taken on 28 Oct 2026
This ranking shows the startups as they stood on 28 Oct 2026. Funding rounds, valuations and other events announced after that date are not included yet. They will be taken into account in the next edition, scheduled for 12 Apr 2027.
Spotted a more recent round? Tell us →First edition: no movements yet.
This ranking shows the startups as they stood on 28 Oct 2026. Funding rounds, valuations and other events announced after that date are not included yet. They will be taken into account in the next edition, scheduled for 12 Apr 2027.
Spotted a more recent round? Tell us →First edition: no movements yet.
World · 25 ranked companies
| # | Company | Last round · Key metrics | AI valuation | Pool of InterestsInterest: a free, non-binding declaration on a company, or on a sector within an area, made during the free phase of a pool. Pool: all the Interests declared on the same target. This column shows the number of Backers and the combined amount of their tickets, to validated members only. Terms for Backers → | BackBacking a startup on Uback (pronounced “you back”) can be done in two ways: Interest · free: a non-binding declaration that signals your demand for a company or a sector. You can move or withdraw it at any time, with up to 5 at once. Intention · coming soon: a paid, confirmed declaration, still non-binding. Once its pool reaches critical mass, it is presented to a company by a partner desk. Neither is an order nor a commitment to invest. Terms for Backers → |
|---|---|---|---|---|---|
| — | NateraListed · Nasdaq · NTRA | USD 28bnMarket cap · Mar 2026Listed company · not ranked | |||
| — | Guardant HealthListed · Nasdaq · GH | USD 12bnMarket cap · Mar 2026Listed company · not ranked | |||
| — | GRAILListed · Nasdaq · GRAL | USD 7.1bnMarket cap · Oct 2026Listed company · not ranked | |||
| 1 | Function HealthMembership health platform that runs over 100 lab biomarker tests a year through partner labs, adds full-body MRI scans and gives members clinician-reviewed insights and action plans. | Series B · USD 298M · Nov 2025More than 50 million lab tests completed since 2023 · Nov 2025 | Last known equity round: Series B · USD 298M · Nov 2025 (Redpoint Ventures; Andreessen Horowitz, Aglaé Ventures, Battery Ventures, NFDG) Published valuation: USD 2.5bn (Nov 2025)Method |
Be the first | Back |
| — | FreenomeListed · Nasdaq · FRNM | USD 1.37bnMarket cap · Oct 2026Listed company · not ranked | |||
| 2 | Delfi DiagnosticsDevelops low-cost blood tests that analyse cell-free DNA fragmentation patterns with machine learning to detect lung and other cancers early, sold through physicians. | Series B · USD 225M · Jul 2022Key metrics not disclosed | Last known equity round: Series B · USD 225M · Jul 2022 (DFJ Growth; Eli Lilly, Point72, Brown Advisory, Cowen Healthcare Investments)Method | Be the first | Back |
| 3 | EverlywellAt-home lab testing company that sells mail-in sample collection kits for wellness, fertility, sexual health and chronic conditions, with physician review and digital results. | Series D · USD 175M · Dec 2020Key metrics not disclosed | Last known equity round: Series D · USD 175M · Dec 2020Method | Be the first | Back |
| 4 | LetsGetCheckedHome health testing company that ships sample collection kits, analyses them in its own accredited labs and adds telehealth consultations and pharmacy services for consumers and employers. | Series D · USD 150M · Jun 2021Key metrics not disclosed | Last known equity round: Series D · USD 150M · Jun 2021 (Optum Ventures)Method | Be the first | Back |
| 5 | Harbinger HealthDevelops blood tests that read epigenetic signals in cell-free DNA with AI to screen for multiple cancers at early stages, starting with high-risk patients. | Undisclosed (after Series B) · USD 100M · Apr 2026Key metrics not disclosed | Last known equity round: Undisclosed (after Series B) · USD 100M · Apr 2026 (Flagship Pioneering)Method | Be the first | Back |
| 6 | KariusOffers a blood test that sequences microbial cell-free DNA to identify more than 1,000 pathogens behind serious infections, used by hospitals to guide treatment. | Series C · USD 100M · May 2024Key metrics not disclosed | Last known equity round: Series C · USD 100M · May 2024 (Khosla Ventures, 5AM Ventures, Gilde Healthcare)Method | Be the first | Back |
| 7 | Truvian HealthBuilds an automated benchtop blood analyser that runs chemistry, immunoassay and haematology tests from one small sample in retail and clinic settings. | Financing round (series not stated) · USD 74M · Jul 2024Key metrics not disclosed | Last known equity round: Financing round (series not stated) · USD 74M · Jul 2024 (Wittington Ventures, Great Point Ventures)Method | Be the first | Back |
| 8 | MirvieDevelops pregnancy blood tests that analyse cell-free RNA to predict complications such as preeclampsia and preterm birth before symptoms appear. | Series B · USD 60M · May 2022Key metrics not disclosed | Last known equity round: Series B · USD 60M · May 2022 (Decheng Capital, Foresite Capital, General Catalyst, GV)Method | Be the first | Back |
| 9 | InflammatixDevelops a rapid blood test and instrument that reads host immune gene expression to tell bacterial from viral infections and assess sepsis risk in emergency departments. | Series E · USD 57M · Sep 2024Key metrics not disclosed | Last known equity round: Series E · USD 57M · Sep 2024 (Khosla Ventures, Think.Health; Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital)Method | Be the first | Back |
| 10 | deepull#23 in SpainDevelops a rapid molecular test that identifies sepsis-causing pathogens and resistance genes directly from whole blood, without prior culture, for hospital labs. | Series C · USD 56M · Apr 2025Key metrics not disclosed | Last known equity round: Series C · USD 56M · Apr 2025Method | Be the first | Back |
| 11 | Visby MedicalMakes single-use, instrument-free PCR tests that give lab-quality results in under 30 minutes, including an at-home sexually transmitted infection test. | Financing round (series not stated) · USD 55M · Jun 2025Key metrics not disclosed | Last known equity round: Financing round (series not stated) · USD 55M · Jun 2025 (Catalio Capital Management; ND Capital, Cedars-Sinai, Blue Water Life Science Advisors, Pitango Ventures)Method | Be the first | Back |
| 12 | HealthiansOffers at-home blood sample collection and lab tests booked online across Indian cities, with health packages for consumers and corporate clients. | Series C · USD 54M · Jan 2022Key metrics not disclosed | Last known equity round: Series C · USD 54M · Jan 2022 (WestBridge Capital; Trifecta Capital, Konark Trust, MMPL)Method | Be the first | Back |
| 13 | Orange HealthProvides fast home blood sample collection and in-house lab testing in Indian cities, with digital reports delivered within hours. | Series C · USD 37.6M · Jun 2026FY25 revenue of USD 11.4M · FY2025 | Last known equity round: Series C · USD 37.6M · Jun 2026 (Iron Pillar India; Crescent Enterprises, Paramark Frontier Fund, Bertelsmann, Good Capital) Published valuation: USD 260M (Jun 2026)Method |
Be the first | Back |
| 14 | Redcliffe LabsRuns a network of diagnostic labs and home sample collection across India, offering routine and specialised blood tests ordered online by patients. | Series C · USD 42M · Sep 2024Key metrics not disclosed | Last known equity round: Series C · USD 42M · Sep 2024 (IFU - Danish Investment Fund for Developing Countries; LeapFrog Investments, HealthQuad, Spark Growth Ventures)Method | Be the first | Back |
| 15 | Craif#38 in JapanDevelops urine-based tests that analyse microRNA in extracellular vesicles with AI to screen for cancers early, sold to clinics and consumers in Japan. | Series D · USD 33.5M · Aug 2026Key metrics not disclosed | Last known equity round: Series D · USD 33.5M · Aug 2026Method | Be the first | Back |
| 16 | AbionicMakes a nanofluidic point-of-care platform that measures blood biomarkers in minutes, with an FDA-cleared test for early detection of sepsis. | Series C · USD 21M · Mar 2018Key metrics not disclosed | Last known equity round: Series C · USD 21M · Mar 2018Method | Be the first | Back |
| 17 | SpotitEarlyOffers at-home breath sample collection kits analysed by trained detection dogs and AI to screen for several common cancers early. | Undisclosed · USD 20.3M · May 2025Key metrics not disclosed | Last known equity round: Undisclosed · USD 20.3M · May 2025 (Hanaco VC, Menomadin)Method | Be the first | Back |
| 18 | PrenosisDevelops AI diagnostic software that combines blood biomarkers and clinical data to assess sepsis risk in hospital patients, with an FDA-authorised Sepsis ImmunoScore. | Series A · USD 20M · Jan 2026Key metrics not disclosed | Last known equity round: Series A · USD 20M · Jan 2026 (PACE Healthcare Capital; Labcorp Venture Fund, Carle Health)Method | Be the first | Back |
| 19 | LucisPreventive health platform that analyses over 110 blood biomarkers through partner labs and uses AI to give members personalised diet, supplement and follow-up recommendations. | Series A · USD 20M · May 2026Over 10,000 users and over 1 million biomarker tests · 2026 | Last known equity round: Series A · USD 20M · May 2026 (Singular; General Catalyst, Y Combinator)Method | Be the first | Back |
| 20 | Lucence#42 in SingaporeDevelops liquid-biopsy blood tests that sequence circulating tumour DNA and viral DNA to detect and profile cancers for patients and physicians. | Series A · USD 20M · Nov 2019Key metrics not disclosed | Last known equity round: Series A · USD 20M · Nov 2019 (IHH Healthcare, SGInnovate, Heliconia Capital)Method | Be the first | Back |
| 21 | Day Zero DiagnosticsDevelops sequencing-based tests that identify bacterial species and antibiotic resistance directly from patient samples to speed treatment of serious infections. | Financing round (series not stated) · USD 16M · Oct 2023Key metrics not disclosed | Last known equity round: Financing round (series not stated) · USD 16M · Oct 2023Method | Be the first | Back |
| 22 | Tethis#35 in ItalyDevelops automated systems that prepare blood and tissue samples on coated slides for liquid biopsy and cancer diagnostics in clinical and research labs. | Funding round · USD 15.5M · Jan 2025Key metrics not disclosed | Last known equity round: Funding round · USD 15.5M · Jan 2025 (Fondazione ENEA Tech e Biomedical, Fondazione Biomedica)Method | Be the first | Back |
| 23 | Ilara Health#20 in KenyaSupplies affordable diagnostic devices, financing and software to primary-care clinics in Kenya so they can run tests and imaging on site. | Series A · USD 3.8M · Feb 2022Key metrics not disclosed | Last known equity round: Series A · USD 3.8M · Feb 2022 (TLcom Capital, DOB Equity, Global Ventures, Chandaria Capital)Method | Be the first | Back |
| 24 | OncoliqDevelops a blood test that measures circulating microRNA and applies machine learning to detect breast and other cancers at early stages. | Seed · USD 2.8M · May 2025Key metrics not disclosed | Last known equity round: Seed · USD 2.8M · May 2025 (Endurance28; Draper U Ventures, Air Capital, Women in Technology, DIM Centros de Salud)Method | Be the first | Back |
| 25 | Redbird#12 in GhanaRuns a pharmacy-based health monitoring platform in Ghana where patients take rapid tests for chronic conditions and track results digitally with their pharmacist. | Seed · USD 1.5M · Mar 2021Key metrics not disclosed | Last known equity round: Seed · USD 1.5M · Mar 2021 (Newtown Partners)Method | Be the first | Back |
Back · Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale. · Terms
Corporate investor? Back the startups of your own segment
No ranked company in this region yet: see the Radar.
Ranking in descending order of AI-estimated valuation, based on public information, with no human intervention on the order. The valuations, ranges and brackets shown are editorial estimates produced by AI, purely indicative and imperfect by nature: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Ranking established by Claude (Anthropic) from public information, following the published rules. A consensus of several AIs will apply from 1 December 2026. Eligibility: at least $1M raised in equity, non-listed company, main activity in this segment (in-vitro diagnostics). Country shown is the country of main operations. Request a correction · Full method →
Get every new ranking
New entries, exits and movements, at every edition.
No data passed on to third parties. See our Privacy policy.
Challengers
A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.
Sponsored space · no Challenger listed yet
Radar · known eligible companies, not ranked
Sorted by date of last round, with no judgement and no AI call.
- Singlera Genomics · China · AsiaJul 2024Not open to BackersCompanies based in mainland China are ranked like any other startup, but Uback does not open pools on them: capital controls and offshore (VIE) structures make minority deals impractical for our Backers.
You can still declare an interest in this segment → - Thriva · United Kingdom · EuropeMay 2020Back
No company on the radar in this region yet.
Listed benchmarks
Not ranked: no intention is possible on a listed company.
- Natera · United StatesNasdaq · NTRA · USD 28bn (Mar 2026)
- Guardant Health · United StatesNasdaq · GH · USD 12bn (Mar 2026)
- GRAIL · United StatesNasdaq · GRAL · USD 7.1bn (Oct 2026)
- Freenome · United StatesNasdaq · FRNM · USD 1.37bn (Oct 2026)
Sources and method for this segment
Calendar. Global segment rankings are published twice a year. Next edition: April 12, 2027.
Eligibility. At least $1M raised in equity, non-listed company, main activity in this segment (in-vitro diagnostics). A company appears in one segment only.
Sources. Company announcements, Bloomberg, Reuters, STAT, Fierce Biotech, GenomeWeb, 360Dx, MedTech Dive, Sifted, Inc42, Entrackr, 36Kr and market data for listed companies.